0000905718-14-000283.txt : 20140522 0000905718-14-000283.hdr.sgml : 20140522 20140522201916 ACCESSION NUMBER: 0000905718-14-000283 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140522 FILED AS OF DATE: 20140522 DATE AS OF CHANGE: 20140522 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGILE THERAPEUTICS INC CENTRAL INDEX KEY: 0001261249 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 101 POOR FARM ROAD CITY: PRINCETON STATE: NJ ZIP: 08540-1715 BUSINESS PHONE: 609-683-1880 MAIL ADDRESS: STREET 1: 101 POOR FARM ROAD CITY: PRINCETON STATE: NJ ZIP: 08540-1715 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: INVESTOR AB CENTRAL INDEX KEY: 0000889232 STATE OF INCORPORATION: V7 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36464 FILM NUMBER: 14865263 BUSINESS ADDRESS: STREET 1: ARSENALSGATAN 8C STREET 2: SE-103 32 CITY: STOCKHOLM STATE: V7 ZIP: 00000 BUSINESS PHONE: 46-8-6142000 MAIL ADDRESS: STREET 1: ARSENALSGATAN 8C STREET 2: SE-103 32 CITY: STOCKHOLM STATE: V7 ZIP: 00000 3 1 agile_form3may2014.xml OWNERSHIP DOCUMENT X0206 3 2014-05-22 0 0001261249 AGILE THERAPEUTICS INC AGRX 0000889232 INVESTOR AB C/O INVESTOR GROWTH CAPITAL, LLC ONE ROCKEFELLER PLAZA, SUITE 2801 NEW YORK NY 10020 0 0 1 0 Series B Preferred Stock 2014-05-22 Common Stock 1950200 I See Footnotes Series C Preferred Stock 2014-05-22 Common Stock 424557 I See Footnotes Convertible Promissory Notes 2014-05-22 Common Stock 135192 I See Footnotes As of May 22, 2014 (the "Effective Date"), certain affiliated entities of Investor AB, a publicly held Swedish company (the "Reporting Person"), hold the securities set forth in Table II above of Agile Therapeutics, Inc., a Delaware corporation (the "Issuer"). As a result of the foregoing, as of the Effective Date, the Reporting Person possesses the sole power to vote and the sole power to direct the disposition of the securities of the Issuer set forth in Table II above. The Reporting Person's interest in the securities of the Issuer set forth in Table II above reported herein is limited to its pecuniary interest, if any, in such securities. The Issuer's Series B Preferred Stock is convertible by the Reporting Person at any time on a 1.4-for-1 basis and will automatically convert into shares of Common Stock on a 1.4-for-1 basis upon the closing of the Issuer's initial public offering and has no expiration date. The Issuer's Series C Preferred Stock is convertible by the Reporting Person at any time on a 1.4-for-1 basis and will automatically convert into shares of Common Stock on a 1.4-for-1 basis upon the closing of the Issuer's initial public offering and has no expiration date. The Issuer's 8% Convertible Promissory Notes (the "Notes") will automatically convert upon the closing of the Issuer's initial public offering into a number of shares of Common Stock equal to the quotient of the aggregate outstanding principal amount and all accrued and unpaid interest due under the Notes divided by the initial public offering price, which is $6.00 per share of Common Stock. Investor AB By: /s/ Michael V. Oporto, Authorized Signatory 2014-05-22